Characteristics of patients who developed pleural effusions
| . | Value (range or %) |
|---|---|
| No. of patients (% of total study population) | 53 (25) |
| Sex | |
| Male/female | 26/27 |
| Median age at effusion onset (range), y | 65 (41-86) |
| Median duration of dasatinib therapy (range) at time of effusion onset, y | 11 (0.5-59) |
| Grade effusion, n (% of all patients with effusion) | |
| 1-2 | 41 (77) |
| 3-4 | 10 (19) |
| No grade provided | 2 |
| Patients per line of therapy, n (% patients receiving this line with effusion) | |
| First | 7 (14) |
| Second | 40 (32) |
| Third | 6 (17) |
| Dasatinib dose at onset, mg, n (% patients receiving this dose with effusion) | |
| 50 | 2* |
| 70 | 4* |
| 80 | 1* |
| 100 | 37 (21) |
| 140 | 9 (43) |
| MR at effusion onset, log reduction, n (% of all patients with effusion) | |
| 0 | 4 (8) |
| MR1 | 7 (13) |
| MR2 | 2 (4) |
| MR3 | 5 (9) |
| MR4 | 7 (13) |
| MR4.5 | 27 (51) |
| No data available | 1 |
| . | Value (range or %) |
|---|---|
| No. of patients (% of total study population) | 53 (25) |
| Sex | |
| Male/female | 26/27 |
| Median age at effusion onset (range), y | 65 (41-86) |
| Median duration of dasatinib therapy (range) at time of effusion onset, y | 11 (0.5-59) |
| Grade effusion, n (% of all patients with effusion) | |
| 1-2 | 41 (77) |
| 3-4 | 10 (19) |
| No grade provided | 2 |
| Patients per line of therapy, n (% patients receiving this line with effusion) | |
| First | 7 (14) |
| Second | 40 (32) |
| Third | 6 (17) |
| Dasatinib dose at onset, mg, n (% patients receiving this dose with effusion) | |
| 50 | 2* |
| 70 | 4* |
| 80 | 1* |
| 100 | 37 (21) |
| 140 | 9 (43) |
| MR at effusion onset, log reduction, n (% of all patients with effusion) | |
| 0 | 4 (8) |
| MR1 | 7 (13) |
| MR2 | 2 (4) |
| MR3 | 5 (9) |
| MR4 | 7 (13) |
| MR4.5 | 27 (51) |
| No data available | 1 |
The percentage of patients with effusion/patients not calculated for starting doses <100 mg due to many subsequent dose fluctuations in these patients.